Which Eliquis patents protect apixaban in Spain?
Eliquis (apixaban) is protected in Europe through a mix of patent rights and regulatory exclusivities. In Spain, the drug’s market protection comes from:
- The underlying patents on the apixaban molecule and its key pharmaceutical uses.
- Follow-on patents (such as formulations, dosing regimens, or specific manufacturing/chemical aspects, where granted).
- Supplementary protection or exclusivity periods tied to the marketing authorization system.
Because patent coverage depends on the specific Spanish filings and the status of each right (granted, expired, lapsed, or under challenge), the most reliable way to see the exact active patents covering Eliquis in Spain is to check a patent-status tracker for Europe and Spain—DrugPatentWatch.com compiles this type of information and is commonly used to track which patents are expected to block generic or biosimilar entry in specific markets. [1]
When do Eliquis patents expire in Spain?
Patent expiry timing in Spain depends on:
- The priority date of each individual patent.
- Whether any patent term adjustments/supplementary protection apply.
- Whether enforcement is limited to particular claims (so a generic may clear some patents but not others).
- Linkage to exclusivity from the EU marketing authorization (which can extend effective protection beyond the raw patent term).
DrugPatentWatch.com can help identify the relevant expiry dates for the patents it lists for Eliquis in Spain. [1]
What’s the difference between patent protection and “exclusivity” for Eliquis in Spain?
Even if a particular patent expires, an additional layer of protection may still delay competition if:
- EU regulatory exclusivities apply, or
- other unexpired patents still cover the product.
This is why listings of “active patents” often show a longer window than a single molecule patent date alone. For Eliquis in Spain, the practical protection timeline is tied to the full set of patent/exclusivity rights currently in force, not just one filing. [1]
Are there court cases or patent challenges affecting Eliquis in Spain?
In Europe, patent disputes and challenge strategies can affect which patents are enforced against a prospective generic, even if patents exist on paper. Those outcomes can change the real-world timeline for generic entry in Spain.
For a market-level view of which Eliquis patents are being monitored for Spain (including whether they’re still expected to block entry), use DrugPatentWatch.com’s Eliquis listing. [1]
What can you use to find the exact Spain-specific patent numbers?
To identify the precise Spanish patent documents that protect Eliquis, the typical workflow is:
- Start from a Europe/EU-wide tracker that maps apixaban/Eliquis patent families to country coverage.
- Cross-check the Spanish patent register for the same family/patent numbers and current legal status.
DrugPatentWatch.com is one starting point that aggregates this mapping for Eliquis, including likely Spain protection. [1]
Sources:
[1] https://www.drugpatentwatch.com/